Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03680092 · ClinicalTrials.gov registry record · Phase 2
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
A Phase 2 study of Hematologic Neoplasms and GvHD, sponsored by Dimitrios Tzachanis, MD PhD.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT03680092: Completed Phase 2 study of Hematologic Neoplasms and GvHD, sponsored by Dimitrios Tzachanis, MD PhD.
NCT03680092 is a Phase 2 study of Hematologic Neoplasms and GvHD that has completed, run by Dimitrios Tzachanis, MD PhD. The registered enrollment target is 43 participants, below the 1,024-participant average among 20 other Hematologic Neoplasms trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03680092, a Phase 2 study of Hematologic Neoplasms and GvHD, has completed, sponsored by Dimitrios Tzachanis, MD PhD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate whether the combination of cyclophosphamide and abatacept versus the treatment used in standard of care will reduce the incidence of moderate and severe chronic graft-versus-host disease (GVHD) following hematopoietic stem cell transplantation. GVHD occurs when the cells from your donor (the graft) see your body's cells (the host) as different and attack them.
Primary Outcome
The occurrence of moderate and severe chronic GVHD at one year post Chronic GVHD will be diagnosed and staged according to the previously published and widely accepted National Institutes of Health consensus criteria
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Tacrolimus
- DRUG Methotrexate
- DRUG abatacept
Study Locations (1)
California
- UC San Diego Moores Cancer Center - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2019-11-26 |
| Est. Completion | 2023-06-15 |
| Phase | Phase 2 |
What the finished NCT03680092 record still lists
NCT03680092 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,024-participant average among 20 other Hematologic Neoplasms trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Hematologic Neoplasms appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT03680092 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03680092 about?
NCT03680092 is a clinical study titled "Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation". The purpose of this study is to investigate whether the combination of cyclophosphamide and abatacept versus the treatment used in standard of care will reduce the incidence of moderate and severe chronic graft-versus-host disease (GVHD) following hematopoietic stem cell transplantation. GVHD occurs...
What is the current status of trial NCT03680092?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2019-11-26. Estimated completion is 2023-06-15.
What conditions does trial NCT03680092 study?
This clinical trial studies the following conditions: Hematologic Neoplasms, GvHD.
What interventions are being tested in trial NCT03680092?
The interventions under investigation include: Cyclophosphamide (DRUG), Tacrolimus (DRUG), Methotrexate (DRUG), abatacept (DRUG).
Who is sponsoring clinical trial NCT03680092?
This trial is sponsored by Dimitrios Tzachanis, MD PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03680092 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03680092's enrollment target sits among peer trials
43 16th of 20 higher than 5 of 20 other Hematologic Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematologic Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil
ACTIVE NOT RECRUITING · Phase 2
-
Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant
COMPLETED · Phase 2
-
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
COMPLETED · Phase 2
-
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant
COMPLETED · Phase 2
-
Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies
COMPLETED · Phase 2
-
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI